Human disease
Sjogren syndrome
Mondo defines it as: “An autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjögren syndrome is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. The hallmark symptoms of Sjögren syndrome are dry mouth and dry eyes. In addition, Sjogren syndrome may cause skin, nose, and vaginal dryness. It also may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 2910 | Sjogren syndrome | Both routes | 2 | Human disease |
42.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Bromhexine | None of these genes | Approved |
| Cevimeline | None of these genes | Approved |
| Pilocarpine | None of these genes | Approved |
| Abatacept | None of these genes | Phase 3 |
| Arsenic | None of these genes | Phase 3 |
| Cravacitinib | None of these genes | Phase 3 |
| Dazodalibep | None of these genes | Phase 3 |
| Epratuzumab | None of these genes | Phase 3 |
| Ianalumab | None of these genes | Phase 3 |
| Insulin Lispro | None of these genes | Phase 3 |
| Nipocalimab | None of these genes | Phase 3 |
| Telitacicept | None of these genes | Phase 3 |
| Fish Oil | None of these genes | Phase 2/3 |
| Hydroxychloroquine | None of these genes | Phase 2/3 |
| Prednisolone | None of these genes | Phase 2/3 |
| Rituximab | None of these genes | Phase 2/3 |
| Tacrolimus Anhydrous | None of these genes | Phase 2/3 |
| Tibulizumab | None of these genes | Phase 2/3 |
| 552-02 | None of these genes | Phase 2 |
| Abiprubart | None of these genes | Phase 2 |
| Amg-557 | None of these genes | Phase 2 |
| Baminercept | None of these genes | Phase 2 |
| Belimumab | None of these genes | Phase 2 |
| Branebrutinib | None of these genes | Phase 2 |
| Bupivacaine | None of these genes | Phase 2 |
| Dexamethasone | None of these genes | Phase 2 |
| Efalizumab | None of these genes | Phase 2 |
| Efgartigimod Alfa | None of these genes | Phase 2 |
| Etanercept | None of these genes | Phase 2 |
| Filgotinib | None of these genes | Phase 2 |
| Frexalimab | None of these genes | Phase 2 |
| Iscalimab | None of these genes | Phase 2 |
| Lanraplenib | None of these genes | Phase 2 |
| Leniolisib | None of these genes | Phase 2 |
| Levocarnitine | None of these genes | Phase 2 |
| Mhv-370 | None of these genes | Phase 2 |
| Mycophenolate Mofetil | None of these genes | Phase 2 |
| Parsaclisib | None of these genes | Phase 2 |
| Petesicatib | None of these genes | Phase 2 |
| Prasterone | None of these genes | Phase 2 |
| Remibrutinib | None of these genes | Phase 2 |
| Rslv-132 | None of these genes | Phase 2 |
| Seletalisib | None of these genes | Phase 2 |
| Sibeprenlimab | None of these genes | Phase 2 |
| Sodium Chloride | None of these genes | Phase 2 |
| Thalidomide | None of these genes | Phase 2 |
| Tirabrutinib | None of these genes | Phase 2 |
| Tofacitinib | None of these genes | Phase 2 |
| Troculeucel | None of these genes | Phase 2 |
| Venanprubart | None of these genes | Phase 2 |
| Aldesleukin | None of these genes | Phase 1/2 |
| Desoxyribonuclease | None of these genes | Phase 1/2 |
| Iguratimod | None of these genes | Phase 1/2 |
| Rapcabtagene Autoleucel | None of these genes | Phase 1/2 |
| Sirolimus | None of these genes | Phase 1/2 |
| 2-Mercaptoethanesulfonic Acid | None of these genes | Phase 1 |
| Alemtuzumab | None of these genes | Phase 1 |
| Antilymphocyte Immunoglobulin (Horse) | None of these genes | Phase 1 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 1 |
| Daxdilimab | None of these genes | Phase 1 |
| Filgrastim | None of these genes | Phase 1 |
| Fludarabine | None of these genes | Phase 1 |
| Gsk2618960 | None of these genes | Phase 1 |
| Lenograstim | None of these genes | Phase 1 |
| Mln3126 | None of these genes | Phase 1 |
| Mycophenolic Acid | None of these genes | Phase 1 |
| Nivolumab | None of these genes | Phase 1 |
| Pegfilgrastim | None of these genes | Phase 1 |
| Ustekinumab | None of these genes | Phase 1 |
| Cyclosporine | None of these genes | Unknown |
| Hydrocortisone | None of these genes | Unknown |
| Rebamipide | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.